BACKGROUND: The aim of the study was to assess the morbidity and efficacy of repeat cryoablation (CA) in the treatment of @entity263 . METHODS: Twenty-seven @entity1 with median age of 71  years (range 48-80) who underwent repeat CA between April 2003 and April 2011 at a single institution were included. The median initial @entity1069 ( @entity1069 ) and Gleason values were 6.2  ng/ml (range 4-23.6) and 7 (range 6-9), respectively. Twenty-four @entity1 underwent two CA treatments, and three @entity1 underwent three CA treatments. Pre- and perioperative parameters and oncological and functional outcomes were evaluated. RESULTS: No intraoperative complications occurred. After the first CA, @entity1069 was undetectable in 10 @entity1 , and the median nadir @entity1069 value was 0.65  ng/ml (range 0.1-4.9). After the second CA, 4 @entity1 had undetectable @entity1069 , and the median nadir @entity1069 value was 1.25  ng/ml (range 0.2-7.9). For @entity1 who underwent a third CA treatment, no @entity1 had undetectable @entity1069 , and the subsequent median nadir @entity1069 value was 1.6  ng/ml (range 0.4-4.5). Two @entity1 had @entity322 (1 pad per day) following repeat CA. One @entity1 had urinary retention after the third CA treatment, and one had urethral stricture. The mean hospitalization and follow-up periods were 1  day (range 0-2) and 51.5  months (range 11-96), respectively. CONCLUSIONS: Repeat CA successfully reduced @entity1069 levels, and complications were modest. We conclude that repeat CA is a feasible, safe, and effective treatment option for @entity263 .

The feasibility and safety of repeat cryosurgical ablation of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1069 :: ('MESH:D053448', 'Disease') :: ['prostate-specific antigens', 'PSA'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer'] @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence']
@entity263 :: (MESH:D011471,Disease) :: ['localized prostate cancer']
